Pancreatin + Alpha GalactosidaseThird Party Manufacturing in India

Pancreatin in combination with Alpha Galactosidase provides comprehensive digestive enzyme replacement therapy. Pancreatin is a mixture of pancreatic enzymes including proteases (trypsin and chymotrypsin), alpha-amylase, and lipase, which work synergistically to break down macronutrients. The proteases hydrolyze proteins into peptides and amino acids, amylase converts complex carbohydrates and starch into simple sugars including maltose and glucose, and lipase breaks down triglycerides into fatty acids and monoglycerides. Alpha Galactosidase complements this action by specifically hydrolyzing alpha-galactosidic bonds found in complex carbohydrates such as raffinose, stachyose, and verbascose present in legumes, beans, and cruciferous vegetables. These oligosaccharides are not digestible by human enzymes alone and pass into the colon where bacterial fermentation produces gas and bloating. By breaking these bonds in the upper gastrointestinal tract, alpha galactosidase prevents gas formation and improves overall digestive comfort. The combination ensures complete macronutrient digestion while addressing the specific gas-producing effects of plant-based foods.

Therapeutic Uses

Pancreatin + Alpha Galactosidase is prescribed for the treatment of:

• Exocrine pancreatic insufficiency (EPI): Helps patients with insufficient pancreatic enzyme production due to chronic pancreatitis, cystic fibrosis, pancreatic cancer, or post-pancreatectomy states.
• Functional dyspepsia and bloating: The alpha galactosidase component specifically targets gas and bloating caused by indigestible carbohydrates in legumes, beans, and vegetables.
• Post-meal digestive discomfort: Provides comprehensive digestive support for patients with non-specific digestive complaints including fullness, flatulence, and abdominal distension.

Why Manufacturers Choose Pancreatin + Alpha Galactosidase

The combination of pancreatin with alpha galactosidase addresses a growing consumer demand for comprehensive digestive health solutions. India, with its large vegetarian population that consumes significant quantities of legumes and pulses, represents a particularly strong market for alpha galactosidase-containing digestive enzyme products. The combination product allows manufacturers to offer a differentiated digestive enzyme formulation that addresses both macronutrient maldigestion and gas-related discomfort. Both pancreatin (CAS 8049-47-6) and alpha galactosidase (CAS 9025-35-8) can be sourced from multiple Indian enzyme manufacturers, ensuring reliable supply chain. The tablet formulation at 150mg+150mg strength is well-established and can be manufactured in WHO-GMP certified facilities for both domestic and export markets. This combination is increasingly popular in the PCD franchise model, where differentiated digestive health products command better margins.